"Health care reform could mean opportunities for astute investors," says Brandon Clay in his Invest With an Edge.
Here, eyes two biotech ETFs that "should be on everyone's watch list." The advisor notes, "With health care on the front burner in Washington, these biotechnology ETFs may finally be ready to pop."
"Investors in health care should think outside the realm of traditional pharmaceutical companies and health insurers. Those sectors are each facing headwinds that make stock picking difficult.
"In addition, several big pharma companiesare desperate to reload their empty pipelines in the face of increased competition from generic drug makers.
Heinz looking good after the second quarter?
Why isn't Bank of America updating its shareholders on CEO situation?
Will Rich Ross really have a positive impact on Disney's movie operations?
